Visceral Hypersensitivity Drives IBS-C Pain & Constipation

A Multifactorial Disorder: IBS-C is More Than Slow Transit

Irritable bowel syndrome with constipation (IBS-C) is more than infrequent bowel movements. A 2026 review in Naunyn Schmiedebergs Arch Pharmacol by Mohamed and colleagues frames it as a disorder of gut-brain interaction driven by at least five interconnected mechanisms. Persistent abdominal pain and constipation arise from a combination of visceral hypersensitivity, where the gut’s nerves overreact to normal stimuli, and dysregulation of the gut-brain axis. This central miscommunication is compounded by intestinal barrier dysfunction, immune system activation, and significant alterations in the gut microbiota—a state known as dysbiosis. These factors collectively disrupt normal motility and secretion, leading to the hallmark symptoms of IBS-C.

Natural Products Target Core IBS-C Pathophysiology

The Heliopolis University-led review highlights that certain natural interventions work by directly modulating the underlying causes of IBS-C, not just the symptom of constipation. For example, peppermint oil acts as an antispasmodic, relaxing intestinal smooth muscle and reducing visceral hypersensitivity, which directly alleviates pain. The herbal formulation STW 5 (Iberogast) exhibits multi-target effects, influencing serotonin signaling, motility, and inflammation.

Soluble fiber from psyllium husk improves stool consistency and transit time, but it also acts as a prebiotic, potentially helping to correct dysbiosis and strengthen the gut barrier. Selected probiotic strains, such as certain Bifidobacterium and Lactobacillus species, are shown to modulate immune function, reduce bacterial overgrowth, and improve barrier integrity. Mohamed’s team notes that the clinical evidence, while positive, is limited by short trial durations and small patient groups, calling for more rigorous, long-term studies.

Time-Restricted Eating Reduces Symptom Burden by 33%

Beyond supplements, meal timing emerges as a powerful behavioral tool. A pilot study from Kristiania University College, published in Nutrients, tested a 10-hour time-restricted eating (TRE) window in IBS patients. Clausen and colleagues found participants reported an average 33% reduction in overall IBS symptom severity after eight weeks. This approach, which involves consuming all daily calories within a consistent 10-hour window (e.g., 9 a.m. to 7 p.m.), supports the migrating motor complex (MMC).

The MMC is the gut’s “housekeeping” wave that clears debris and bacteria between meals. A prolonged overnight fast strengthens these cleansing waves, which may help manage bacterial overgrowth and improve motility—key factors in IBS-C. The study’s authors acknowledge the need for larger, controlled trials but suggest TRE is a low-risk, accessible strategy for symptom management. For more on the mechanics of this finding, see our article on Time-Restricted Eating & IBS-C Relief Strategies.

Constructing a Multi-Target Management Plan

This research points toward an integrated management strategy for IBS-C. The goal is to address several pathophysiological pathways simultaneously: calming visceral hypersensitivity, regulating motility, supporting a healthy microbiome, and protecting gut barrier function.

A first-line approach could combine a soluble fiber like psyllium with a time-restricted eating pattern to regulate motility and support microbial health. For persistent pain and bloating, adding enteric-coated peppermint oil or a studied multi-herbal extract like STW 5 may provide targeted relief. Introducing a clinically studied probiotic strain can further support microbiome balance and immune modulation. It is essential to note that individual responses vary significantly; a supplement or diet that helps one person may not help another, underscoring the condition’s heterogeneity.

Furthermore, accurate diagnosis is critical. Symptoms of IBS-C can overlap with other conditions like sucrose malabsorption, which is found in 22% of SIBO-negative patients. A comprehensive approach, therefore, starts with proper testing to rule out confounding issues.

Conclusion

Managing IBS-C effectively requires moving beyond generic fiber and laxatives. Current evidence supports a combination of pathophysiology-driven natural products and behavioral interventions like time-restricted eating. This multi-target strategy addresses the complex interplay of gut-brain axis dysfunction, motility issues, and dysbiosis that defines the condition.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42065756/
https://pubmed.ncbi.nlm.nih.gov/41829935/